G TPase-acTivaTing ProTeins of aDP-ribosylaTion facTors (arfgaPs) form a family of proteins that regulate the small gTPase aDP-ribosylation factors (arfs). [1] [2] [3] six distinct arfs in mammals cycle between guanosine diphosphate (gDP)-bound, inactive forms and guanosine triphosphate (gTP)-bound, active forms to control diverse biological processes, including vesicle trafficking and cytoskeleton reorganization. guanine nucleotide exchange factors of arfs (arfgefs) catalyze the formation of active gTP-bound arfs, whereas arfgaPs promote arf inactivation by stimulating gTP hydrolysis ( Fig. 1) . Unlike other small gTP-binding proteins, such as ras-and rho-family proteins, the intrinsic gTPase activity of arfs is almost undetectable in the in vitro gTPase assays. The involvement of gTPase-activating proteins is thus crucial for the regulation of arf activities.
The human genome encodes at least 31 arfgaPs, among which approximately 17 show in vitro arfgaP enzymatic activity. 3 based on domain structures, the arfgaPs have been grouped into 10 families. other than the zinc finger region that is characteristic of the gaP domain, arfgaPs share little homology. This zinc finger motif, cX 2 cX 16-17 cX 2 c (where c represents cysteine, whereas X can be any amino acid), is the major element that differentiates arfgaPs from other families of gTPase-activating proteins.
Most arfgaPs contain multiple domains, with many of them acting as protein-or lipid-interacting modules. The known arfgaP-interacting proteins are diverse, including those involved in membrane trafficking, actin cytoskeleton reorganization, and cell signaling. 4 These interacting proteins constitute one major way to regulate arfgaP activities in vivo. other than proteinprotein interactions, arfgaPs are also regulated by protein-lipid interactions. [5] [6] [7] [8] for example, phosphoinositides such as phosphatidyl-4,5-bisphosphate (PiP 2 ) and phosphatidyl-3,4,5-triphosphate (PiP 3 ) play crucial roles in the regulation of recruitment and activity of arfgaPs such as the aDaP (arfgaP with dual PH domains) and araP (arfgaP with rhogaP domain, ankyrin repeat, and PH domain) isoforms, as well as giT1 (g-proteincoupled receptor kinase interacting target 1). because phospholipids are not randomly distributed in cellular membranes, protein-phospholipid interactions might be used to determine the substrate specificity of an arfgaP within a particular membrane region. 9 in addition, arfgaPs are regulated by posttranslational modifications such as phosphorylation. 10 arfgaP proteins have been implicated in various diseases. for example, high-grade uveal melanomas and metastatic breast cancer cells significantly overexpress both the messenger rna (mrna) and encoded protein for asaP1 (arfgaP with sH3 domain, ankyrin repeat, and PH domain 1), an arfgaP and oncogene located in the amplified region of chromosome 8q. 11, 12 furthermore, expression of asaP1 in low-grade melanoma cells causes increased cell motility that indicates progression to a high-grade phenotype. in addition, small interfering (sirna) against asaP1 reduced cell migration of human metastatic MDa-Mb-231 cells overexpressing asaP1. 12 a recent report also demonstrates that asaP1 expression correlates with poor metastasis-free survival and prognosis in colorectal cancer patients, further supporting the notion that asaP1 represents a potential target for cancer therapy. 13 arfgaPpaxillin-cortactin complexes have also been proposed as targets for metastatic cancer drugs. 14, 15 another member of the arfgaP family, aDaP1, is a brain-specific inositol phosphate iP 4 /PiP 3 -binding protein that is localized in neurons of the human brain. 16 in alzheimer disease (aD), the expression of aDaP1 is elevated. 17 in addition, aDaP1 interacts with casein kinase i and nucleolin, suggesting that the upregulated aDaP1 in aD neurons may serve as a docking protein to recruit signaling molecules such as different subtypes of casein kinase i to the plasma membrane. 18, 19 This functional interaction of aDaP1 in possible neuronal damage may make it an appropriate target for preventing neurodegenerative processes. 20 finally, agaP1 (arfgaP with gTPase domain, ankyrin repeat, and PH domain 1) has been regarded as an autism susceptibility gene. 21 consequently, regulation of arfgaP functions has the potential to be a novel approach to treat cancer and/or neurodegenerative diseases.
Despite the implications of arfgaPs in various diseases, it is not clear how the overexpression of arfgaPs leads to a specific disease state. small-molecule arfgaP modulators will be invaluable tools to dissect arfgaP-regulated cell signaling and further validate arfgaPs as drug targets. However, there is only one small-molecule inhibitor of arfgaPs described in the literature, 22 and current assays of arfgaP activity are not amenable to high-throughput screening (HTs).
conventional arfgaP activity assays have relied on hydrolysis of either [α 32 P]gTP or [γ 32 P]gTP. 23, 24 These methods require separation of guanine nucleotides either by thin-layer chromatography or filter binding, making them difficult, if not impossible, to modify for high throughput. More recently, fluorescent derivatives (n-methyl-3′-o-anthranoyl [ManT] and boDiPy) of guanine nucleotides have been developed 25, 26 and used to monitor the loading and hydrolysis of gTP by g-proteins and ras-related gTPases. [27] [28] [29] [30] However, these reagents have not been applied to arf activity assays, and our results (data not shown) suggest that the fluorescent gTP derivatives cannot be effectively loaded to arf1. clearly, a high-throughput arfgaP assay that can be used for development of small-molecule regulators is needed.
in our efforts to dissect arfgaP-regulated cell signaling, we have developed a novel assay to monitor arfgaP activity using fluorescence polarization. The Z′ factor of the assay is 0.76 in a 384-well format. When applied to a pilot screen of the library of Pharmacologically active compounds 1280 (loPac1280; sigma-aldrich, st. louis, Mo), the assay demonstrated high reproducibility, reasonable hit rates, and suitability for automation. This advance represents the first assay of arfgaP enzymatic activity that is not based on radiolabeled gTP analogs and will allow the large-scale screening of compound libraries to identify inhibitors of arfgaPs.
MAtErIALS And MEtHodS

Expression and purification of ARFGAPs and ARF1
Three different arfgaPs, including rat arfgaP1, human asaP1, and human stromal membrane-associated gTPaseactivating protein 2 (sMaP2), are used in this work. The expression constructs for the gaP domain of rat arfgaP1 (His 6 -[1-136]arfgaP1), 31 His 6 -[325-724]asaP1, 32 and gsT-[1-163]sMaP2-His 6 33 were obtained from Drs. Jonathan goldberg (Memorial sloan-Kettering cancer center, new york, ny), Paul randazzo (national cancer institute, frederick, MD), and Masanobu satake (Tohoku University, sendai, Japan), respectively. soluble arf1 lacking its n-terminal 17 amino acids was used for assay development; the corresponding expression construct was obtained from Dr. Jonathan goldberg. all four proteins were expressed and purified according to literature protocols. [31] [32] [33] 
Native gel assay
native gel assays were carried out as described. 31 briefly, purified arf1 (1.7 mM, 4 µl) was loaded with gTP (5 mM, 4 µl) by incubating the protein with gTP in the loading buffer (25 mM HePes, 150 mM nacl, 1 mM Mgcl 2 , 5 mM eDTa, 2 mM dithiothreitol [DTT], pH 7.5) at room temperature for 40 min. a solution of Mgcl 2 (2 M) was then added to a final concentration of 20 mM, and arf-gTP was stored at 4 °c prior to use. To carry out the native gel assay, arf-gTP (170 µM, 1.9 µl) and arfgaP1 (15 µM, 4.3 µl) were incubated in the assay buffer (25 mM HePes, 150 mM nacl, 20 mM Mgcl 2 , 5 mM eDTa, 2 mM DTT, pH 7.5) for indicated times at room temperature. The mixtures were then loaded onto Phastgel homogeneous 20% polyacryamide gels (ge Healthcare life sciences, Piscataway, nJ) under non-denaturing conditions, subjected to electrophoresis at 4 °c, and visualized by coomassie blue staining.
Fluorescence polarization assay
a solution of the gaP domain of rat arfgaP1 (5 µM, 4 µl) in the buffer (25 mM HePes, 150 mM nacl, 20 mM Mgcl 2 , 5 mM eDTa, 2 mM DTT, pH 7.5) was added to each well that contained arf1-gTP (2.5 µM, 16 µl) in a 384-well plate. The arf1-gTP was generated as described in the native gel assay. The reaction mixture was incubated at room temperature for varying times, and the enzymatic reaction was terminated by adding the stop and detection buffer (10 µl [bellbrook labs, Madison, Wi], containing 20 mM HePes, 40 mM eDTa, 0.02% brij-35, 4 nM gDP alexa 633 (invitrogen, carlsbad, ca) tracer, and 14 µg/mg gDP antibody). The fluorescence polarization was measured 20 min after adding the detection buffer on a Pe envision 2103 Multilabel reader (Perkinelmer, Waltham, Ma) with an excitation wavelength of 620 nm (bandwidth 40 nm) and an emission wavelength of 688 nm (bandwidth 45 nm). for the measurement, the focal point of the optical system and the detector gains were optimized to maximize the signal-to-noise ratio and the sensitivity according to the manufacturer's protocol. The g factor, a correction factor that is used when light is not transmitted equally through both parallel and perpendicularoriented polarizers, was then recorded and used for measurement of the fluorescence polarization. each reaction was carried out in triplicate, and graphPad Prism 5 (graphPad software, la Jolla, ca) was used to analyze the data.
Screening of the LOPAC1280 chemical library
The small-molecule compounds from the loPac1280 (sigma-aldrich) were dissolved in DMso to form stock solutions (1 mM). The stock solutions were further diluted with arfgaP assay buffer to generate working solutions (100 µM).
To carry out the screen, working solutions of compounds (2 µl) were added to the gaP domain of rat arfgaP1 (5 µM, 4 µl) in assay buffer (10 µl). The plate was incubated at room temperature for 10 min, and arf1-gTP (10 µM, 4 µl) was subsequently added to initiate the reaction. after 2 h, the enzymatic reaction was stopped by adding the stop and detection buffer (10 µl), and the fluorescence polarization was read as described above. each reaction was carried out in duplicate.
rESuLtS And dIScuSSIon
Development of a fluorescence polarization assay of ARFGAP activity
fluorescence polarization (fP) assays 34 have been successfully used to identify small-molecule inhibitors of proteinprotein interactions. Polarization is a measure of the change in the molecular movement of a labeled species and is defined as the ratio of the difference between the vertical and horizontal components of the emitted light over their sum. because polarization is a dimensionless value, it is independent of the emitted light or the concentration of the fluorophore. These features make fP-based assays highly suitable for HTs of compound libraries.
recently, the bellbrook labs has developed a fluorescence polarization-based Transcreener assay that measures gDP levels as a function of the displacement of a fluorescent analogue of gDP initially bound to an antibody ( Fig. 2A) . We have used this format to monitor the capacity of the gaP domain of rat arfgaP1 (residues 1-136) to enhance the intrinsic gTPase activity of human arf1 lacking its first 17 residues. although using the gaP domain instead of the full-length arfgaP1 might potentially miss allosteric inhibitors, the His 6 -[1-136]arfgaP1 has better solubility than the full-length protein and can be produced in bacteria in large quantities. These proteins were purified to homogeneity ( Fig. 2B ) and shown to be active based on the conversion of arf1-gTP to arf1-gDP catalyzed by arfgaP1 and monitored by differential mobility during native gel electrophoresis (Fig. 2c) .
The Transcreener assay works best when the initial gTP concentration is within the range of 1 to 10 µM (www.bellbrooklabs .com). accordingly, we started the assay development with arf1-gTP at the concentration of 2 µM. Three different concentrations (0.5, 1, or 2 µM) of arfgaP1 were used to optimize the reaction conditions. Using the Transcreener assay, the capacity of arfgaP1 to enhance the gTPase activity of arf1-gTP is monitored by the reduction in fluorescence polarization (Fig. 2d) . in this case, a fluorescent tracer version of gDP (gDP alexa 633) is initially antibody bound, and its fluorescence polarization in mP (milli-polarization) is high. free gDP, produced upon hydrolysis of gTP by arf1, displaces the tracer from the antibody, leading to decreased fluorescence polarization. Under these conditions, arfgaP1 in the presence of arf1-gTP reduced fluorescence polarization ~2.5-fold in 2 h with excellent reproducibility (Fig. 2d ) when 1 µM arfgaP1 was used. The fluorescence polarization of the equivalent sample without arfgaP1 remained unchanged during the course of the assay, indicating that arf1-gTP alone has negligible gTPase activity in this format. The stable baseline also indicates that the excess gTP remaining after the loading of arf1 with gTP has no effect on the assay. This point is confirmed by the fact that removal of the excess gTP from arf1-gTP by size exclusion chromatography had no effect on the capacity of arfgaP1 to catalyze gTP hydrolysis in the Transcreener assay (Supplemental Fig. S1 ). To ensure that the assay conditions are applicable for inhibitor development, the kinetics of the arfgaP1-catalyzed hydrolysis of arf1-gTP was measured. The amount of hydrolyzed gTP was measured for different concentrations of arf1-gTP ( Fig. 2E) by using radiolabeled [γ 32 P]gTP. The plot of the initial velocity versus arf1 concentration was fitted to the Michaelis-Menton equation, and the K m was estimated as 73.4 µM, consistent with the literature value when truncated arf1 was used. 35 These data collectively suggest that this fP-based assay is suitable for identifying small-molecule inhibitors of arfgaPs.
several further aspects of this assay reinforce its potential utility for HTs of compound libraries for modulators of arfgaPs. for example, to correlate mP changes with percentage of gTP hydrolyzed, we generated a standard curve using defined gTP/gDP ratios and buffer conditions identical to the enzymatic assay (Supplemental Fig. S2 ). from these data, it is clear that up to 20% conversion of gTP to gDP can be effectively detected by the Transcreener assay, suggesting that the assay is ideal for performing arfgaP assays under initial rate conditions. similarly, the rate of mP change increased with increasing concentration of arfgaP1 and arf1 (Fig. 2d) , making it feasible to tune the length of the assay to accommodate potential constraints, such as plate-handling routines imposed by available screening facilities.
Scope of the fluorescence polarization assay
at least 31 arfgaPs are encoded in the human genome. of this group, at least 17 have the capacity to increase gTP hydrolysis catalyzed by arfs. 3 To test the general applicability of the Transcreener assay to monitor gTP hydrolysis enhanced by arfgaPs other than arfgaP1, two additional arfgaPs were tested (Fig. 3) . Human His 6 -[325-724]asaP1 and gsT-[1-163]sMaP2-His 6 were purified using published protocols (Fig. 3A) 23, 32 ; as shown in Figure 3B , both proteins enhanced the hydrolysis of gTP bound to arf1. although the kinetic profiles are not identical due to possible differences in enzymatic efficiency, it is clear that this new assay format can be used to measure the hydrolysis of gTP by arf1 that is stimulated by various arfgaPs.
Assay development toward HTS
in the design and validation of HTs assays, an assessment of the screening data variability, by measures such as standard deviation (sD) and Z′ factor, is critical in determining whether an assay can identify hits with confidence. 36 Z′ factor is a screening coefficient that reflects the quality of both the assay window and the data variation. To measure the Z′ factor in our assay, 24 parallel experiments in which the arf1-gTP was incubated with either the gaP domain of rat arfgaP1 (positive control) or the reaction assay buffer (negative control) at room temperature for 2 h were carried out, and the fluorescence polarization was recorded (Fig. 4A) . from these data, the calculated Z′ factor is 0.76, indicating that the quality of the assay is high. The Z′ factors for two other arfgaPs were also measured, with 0.70 for sMaP2 and 0.88 for asaP1. furthermore, we tested the effect of increasing DMso concentrations on the change of fluorescence polarization in the reaction (Fig. 4B) . The assay is robust and tolerates up to 10% DMso in 384-well plates.
Screen of the LOPAC1280 collection
To further demonstrate the utility of this assay to identify arfgaP regulators in the 384-well format, we screened the loPac1280 collection of 1280 pharmacologically active compounds. The screen was carried out in duplicate, and the mean of the duplicates of each well is plotted (Fig. 5A) . in each assay plate, DMso was used as the negative control (low signal in mP), whereas the assay buffer instead of arfgaP1 was used in the reaction to function as the positive control (high signal in mP). The average Z′ factor was 0.73 when both intra-and interplate variations were considered. The hit rate was 0.31% for compounds (10 µM) exhibiting more than 3 standard deviations from the mean of the plate in the fluorescence polarization reading. The correlation coefficient for the parallel runs was 0.98 ( Fig. 5B) , further demonstrating that the assay exhibits excellent characteristics for a high-throughput screen.
in summary, we have developed a robust high-throughput screen that will be useful to identify small molecules that modulate the capacity of arfgaPs to enhance the gTPase activity of arfs. compared to traditional arfgaP assays based on radiolabeled gTP analogs, this methodology uses fluorescence polarization to monitor gTP hydrolysis. because no radioactivity is required, this new screening format eliminates the handling of hazardous waste. nonetheless, reliance on fluorescence polarization is not without potential limitations. for example, compounds that directly interfere with fluorescence polarization could be misinterpreted as potential leads. Perhaps more relevant, any compound that affected the affinity of (1) the antibody to bind the fluorescent tracer or (2) the arf gTPase to bind guanine nucleotides might also be misinterpreted as a potential modulator. consequently, secondary assays such as measuring the direct binding of compounds with arfgaPs have to be developed to confirm the arfgaP inhibition in the fluorescence polarization assay. in conclusion, this newly developed assay is ideal for measuring arfgaP activity in large numbers of samples and should be particularly useful for the HTs of compound libraries to identify small-molecule modulators of arfgaPs.
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